Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2024-11-20 Report Publication Anno…
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
OPKO Health to participate in the Piper Sandler 36th annual healthcare conference
Report Publication Announcement Classification · 99% confidence The document is a short press release announcing that OPKO Health's management will be participating in the 'Piper Sandler 36th Annual Healthcare Conference' and will hold one-on-one meetings and a fireside chat. This type of announcement, detailing management's schedule for investor engagement at an industry event, is not explicitly covered by most specific codes (like ER, 10-K, CT). It is an announcement about future investor relations activities. Since it is not a formal report, a dividend notice, a director dealing, or a major regulatory filing, the most appropriate general category for investor-focused announcements that don't fit elsewhere is 'Regulatory Filings' (RNS), as it serves as a general regulatory disclosure about management availability for investors. However, given the context of investor engagement and conference participation, it is often treated as a general corporate update. Since there is no specific code for 'Conference Participation Announcement', RNS is the best fit as a general disclosure.
2024-11-20 English
OPKO Health to participate in the Piper Sandler 36th annual healthcare conference
Report Publication Announcement Classification · 98% confidence The document is very short (1874 characters) and explicitly states, "Attached hereto is a report on*OPKO Health to participate in the Piper Sandler 36th annual healthcare conference* *20241120Form4_isa.pdf*". This structure indicates that the primary purpose of this filing is to announce the publication of an attached document (a conference participation notice, likely related to investor relations or a specific event) rather than being the full report itself. This aligns perfectly with the definition of a Report Publication Announcement (RPA), which covers announcements regarding the release or publication of company reports/information. It is not a standard 10-K, ER, or IR, but rather a notification of related material.
2024-11-20 English
Schedule 13D/A-Phillip Frost, M.D
Major Shareholding Notification Classification · 100% confidence The document explicitly states it is a "SCHEDULE 13D/A" filed "Under the Securities Exchange Act of 1934 (Amendment No. 25)" with the "SECURITIES AND EXCHANGE COMMISSION". Schedule 13D filings relate to the beneficial ownership of more than 5% of a class of a company's securities. This type of filing is not explicitly listed in the provided definitions (AGM-R, 10-K, AR, etc.). Schedule 13D/A is a specific type of regulatory filing concerning insider/significant ownership changes, which does not map directly to the provided codes like DIRS (Director's Dealing) or MRQ (Major Shareholding Notification), as 13D is a comprehensive disclosure form. Given the options, the most appropriate fallback category for a specific, non-standard SEC filing that doesn't fit the other defined categories (like earnings, management changes, or proxy materials) is the general regulatory filing category.
2024-11-16 English
Schedule 13D/A-Phillip Frost, M.D
Regulatory Filings Classification · 95% confidence The document explicitly mentions 'Schedule 13D/A' and references the 'Israel Securities Authority' and 'Tel Aviv Stock Exchange'. Schedule 13D/A is an amendment to a Schedule 13D filing, which reports beneficial ownership of more than 5% of a class of a company's securities. This type of filing relates to significant share ownership changes or acquisitions. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the closest fit for reporting changes in significant share ownership, although Schedule 13D is a specific US SEC filing type. Since the document is an official regulatory report detailing a change in ownership (indicated by '/A' for amendment) and is not a general announcement of a report, it should be classified based on its content. 'MRQ' covers notification of changes in significant share ownership levels, which aligns with the purpose of a Schedule 13D/A. The document length is moderate, suggesting it contains the substance, not just an announcement of attachment.
2024-11-16 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing Classification · 100% confidence The document text explicitly contains the header "FORM 4" and references sections related to the Securities Exchange Act of 1934, specifically concerning the "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES." Form 4 is the standard SEC filing used to report insider transactions (changes in beneficial ownership) by directors, officers, and 10% owners of a company. This directly corresponds to the definition of Director's Dealing (DIRS).
2024-11-16 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement Classification · 98% confidence The document is a short regulatory filing (1768 characters) issued by OPKO HEALTH, INC. It is titled 'Immediate Report' under Regulation 4 concerning a 'interested party transaction'. Crucially, the text states, 'Attached hereto is a report on *interested party transaction* *20241116Form4_isa.pdf*'. This structure—a brief announcement stating that a specific report is attached or published—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. While the content relates to a transaction, the document itself is the announcement of the attached report, not the detailed report (which would likely be classified as LTR or potentially a specific transaction filing if one existed, but RPA is the best fit for the announcement wrapper).
2024-11-16 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.